Compugen Net Change in Intangible Assets 2010-2025 | CGEN

Compugen net change in intangible assets from 2010 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.

Compugen Net Change in Intangible Assets 2010-2025 | CGEN

Compugen net change in intangible assets from 2010 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.1B
Amgen (AMGN)$153.8B
Gilead Sciences (GILD)$139.7B
Vertex Pharmaceuticals (VRTX)$100.5B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$80.3B
CSL (CSLLY)$66.8B
Regeneron Pharmaceuticals (REGN)$61.4B
Alnylam Pharmaceuticals (ALNY)$59.3B
Argenex SE (ARGX)$43.1B
Insmed (INSM)$28.5B
BioNTech SE (BNTX)$24.5B
Royalty Pharma (RPRX)$20.8B
Biogen (BIIB)$19.4B
Genmab (GNMSF)$16.4B
Incyte (INCY)$16.3B
Genmab (GMAB)$16.1B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.5B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.5B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.2B